4//SEC Filing
White Mark K. 4
Accession 0001104659-20-010935
CIK 0001477845other
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 6:02 AM ET
Size
16.2 KB
Accession
0001104659-20-010935
Insider Transaction Report
Form 4
White Mark K.
Director
Transactions
- Conversion
Common Stock
2020-01-31$4.80/sh+3,252$15,610→ 51,177 total - Conversion
Series A Preferred Stock
2020-01-31−48,500→ 0 total→ Common Stock (34,643 underlying) - Purchase
Common Stock
2020-01-31$6.00/sh+1,734$10,404→ 1,734 total - Conversion
Common Stock
2020-01-31+11,548→ 13,282 total - Conversion
Common Stock
2020-01-31+34,643→ 47,925 total - Conversion
Series A-1 Preferred Stock
2020-01-31−16,167→ 0 total→ Common Stock (11,548 underlying) - Conversion
Convertible Note
2020-01-31$4.80/sh−3,252$15,610→ 0 total→ Common Stock (3,252 underlying)
Footnotes (4)
- [F1]The reporting person acquired these shares in the initial public offering ("IPO") of Annovis Bio, Inc. ("Annovis").
- [F2]Each share of Series A-1 Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- [F3]Each share of Series A Preferred Stock automatically converted into common stock of Annovis upon the closing of the IPO at a conversion ratio of one for 0.7143.
- [F4]The convertible notes have a maturity date of December 31, 2023. The Convertible Notes automatically converted into common stock of Annovis upon the closing of the IPO at a conversion rate equal to the principal amount of the note, plus accrued and unpaid interest, divided by $4.80 (80% of the IPO price).
Documents
Issuer
Annovis Bio, Inc.
CIK 0001477845
Entity typeother
Related Parties
1- filerCIK 0001786183
Filing Metadata
- Form type
- 4
- Filed
- Feb 4, 7:00 PM ET
- Accepted
- Feb 5, 6:02 AM ET
- Size
- 16.2 KB